Nov 25 (Reuters) - Spectrum Pharmaceuticals Inc :
* SPECTRUM PHARMACEUTICALS RECEIVES COMPLETE RESPONSE LETTER FROM U.S. FOOD AND DRUG ADMINISTRATION FOR POZIOTINIB; REAFFIRMS FOCUS ON THE COMMERCIALIZATION OF ROLVEDON™ (EFLAPEGRASTIM-XNST) INJECTION
* SPECTRUM PHARMACEUTICALS INC - TO EXPLORE STRATEGIC ALTERNATIVES FOR POZIOTINIB PROGRAM, INCLUDING PARTNERSHIPS AND BUSINESS DEVELOPMENT OPPORTUNITIES
* SPECTRUM PHARMACEUTICALS-IMMEDIATELY DE-PRIORITIZES POZIOTINIB PROGRAM, ACCELERATES COST REDUCTIONS, INCLUDING 75% REDUCTION IN RESEARCH AND DEVELOPMENT RELATED WORKFORCE
* SPECTRUM PHARMACEUTICALS INC - FDA ISSUED A CRL INDICATING POZIOTINIB APPLICATION CANNOT BE APPROVED IN ITS PRESENT FORM
* SPECTRUM PHARMACEUTICALS INC - BASED ON CRL, CO WOULD HAVE TO GENERATE ADDITIONAL DATA INCLUDING A RANDOMIZED CONTROLLED STUDY PRIOR TO APPROVAL
* SPECTRUM PHARMACEUTICALS INC - WILL FOCUS EFFORTS ON DRIVING GROWTH FOR RECENTLY LAUNCHED COMMERCIAL DRUG, ROLVEDON
* SPECTRUM PHARMACEUTICALS INC - BELIEVES IT WILL BE ABLE TO GENERATE WORKING CAPITAL REQUIRED TO SUPPORT ITS STRATEGIC REFOCUSING THROUGH 2024 Source text for Eikon: Further company coverage: